Abstract
The antidepressant effects of neuroactive steroid positive allosteric modulators of GABAA receptors (GABAAR PAMs) likely involve extrasynaptic GABAAR. PRAX-114 is a novel GABAAR PAM with preference for extrasynaptic GABAAR, which is hypothesized to improve tolerability. Here we compared the therapeutic window of PRAX-114 and zuranolone, using EEG β-power as a biomarker of GABAAR potentiation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
